MEDP Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -9.96%, SMA50 -8.43%, SMA200 13.41%). The stock’s 14-day RSI is 29.81 (weak momentum), while the ATR of 20.94 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -15.67% below its high and over 112.1% above its low. Average 10-day trading volume of 428.95 thousand shares is significantly above the 3-month average of 251.84 thousand, indicating heightened recent market interest.

Medpace Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $530.17. This means the shares are trading near this model’s fair value.

Medpace Holdings, Inc. (NASDAQ:MEDP) closed at $530.35 USD, losing -$11.69 (-2.16%) from the previous close of $542.04. The stock is currently mid-range between its 52-week high and low $250.05 and $628.92. With a market capitalization of about $14.94 billion, Medpace Holdings, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 250.36 thousand shares, trading with heavier-than-usual volume. Headquartered in Cincinnati, OH, Medpace Holdings, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO August James Troendle, the company employs approximately 5,900 people and listed since August 11, 2016. Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

Medpace Holdings, Inc. generated EPS of $14.30 over the past year. Five-year average earnings growth is 36.5%. Wall Street analysts project EPS growth of 13.91% annually over the next five years. The latest quarter delivered EPS of $3.86. The next quarter is forecast at $4.19. Next year's EPS is expected at $15.94. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 0 Buy ratings, 10 Hold ratings, 3 Sell rating and 3 Strong Sell ratings. Price targets range from $655.00 to $300.00. The high target offers 23.5% upside. The low target suggests -43.43% downside. The mean target is $447.80. This offers -15.57% upside. Medpace Holdings, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 22, 2025, missed forecasts by 10.29%. The prior quarter beat by 4.03%. Over the last six quarters, Apple has recorded several small beats. These include 9.13% in July 22, 2024.

Medpace Holdings, Inc. has 28.09 million shares outstanding. The public float is 22.22 million shares, elevated short interest at 11.27% of float. This equals 2.50 million shares. The short ratio is 3.6 days. Institutional investors hold 122.04% of the float. Insiders own 20.7%. Medpace Investors, LLC holds 4.73 million shares, Troendle August J. has 646.18 thousand shares and BURWIG SUSAN E has 27.50 thousand shares. Over the past six months, insider transactions show net selling. They sold 443.30 thousand shares across 30 transactions.

Medpace Holdings, Inc. trades at a P/E ratio of 36.04, slightly above the S&P 500 average, with a price-to-sales ratio of 6.42 and a price-to-book ratio of 53.14 reflecting a rich premium to book value. The P/FCF stands at 21.52, also above market averages. Compared to sector medians, Medpace Holdings, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Medpace Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.45%, with price expected at $474.94 by February 23, 2026, within a range of $461.23 to $490.29 3-Month Outlook: Projected fall of -46.33%, reaching $284.66 by May 07, 2026, with a range of $269.90 to $298.36. 1-Year Outlook: Projected gain of 23.71%, with price at $656.08 by February 09, 2027, within a range of $632.39 to $682.46.

Medpace Holdings, Inc. (NASDAQ:MEDP) shares are flat 7.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Medpace Holdings, Inc. trading at a premium to the broader market with a P/E of 36.04. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $358.86, suggesting -32.34% downside. Our AI forecast model points to short-term weakness (-10.45% over two weeks), a medium-term fall (-46.33% over three months), and a longer-term gain (23.71% over one year), with expected trading ranges indicating moderate volatility.